▎Edited by the WuXi AppTec content team

On November 14, MingMed announced that its controlled biopharmaceutical innovation companyChongqing Yuyan Pharmaceutical Co., Ltd.Signed an equity investment agreement with Xinkeli Aesthetics, a wholly-owned subsidiary of Huadong Medicine, Hangzhou Industrial Investment Co., Ltd., and Hangzhou Gongshu State Investment Industry Development Co., Ltd. In addition, Huadong Medicine and Chongqing Yuyan Pharmaceutical Co., Ltd. announced the signing.Injectable Recombinant Botulinum Toxin Type AYY001 Exclusive Distribution Agreement, Establishing a Strategic Partnership.

YY001 is a recombinant Type A botulinum toxin protein independently developed by Chongqing Yuyan Pharmaceutical Co., Ltd. Using gene recombination and protein expression technology, Yuyan Pharmaceutical developed it through its unique...Enzyme Activation MechanismAndInnovative Purification ProcessProduction of high-purity 150kDa single active protein with consistent biological functions and pharmacological effects as natural botulinum toxin.YY001Expected biological functions of Botulinum Toxin Type A were demonstrated in both preclinical animal studies and clinical trials. The product has successfully completedImprovement of Moderate to Severe Glabellar LinesThe Phase 1/2 clinical trial in China has been completed and met the pre-specified primary endpoint. Chongqing Yuyan Pharmaceutical Co., Ltd. is now fully advancing the Phase 3 clinical trial of YY001.

Chief Technology Officer of MingMedDr. Ouyang HuiPreviously received by WuXi AppTec Content TeamInterviewIt was previously introduced that one of MingMed's research and development differentiations is reflected in the botulinum toxin field. The company’s developed recombinant botulinum toxin type A for injection, YY001, has the potential advantages of requiring less protein for clinical treatment and being safer. "YY001 innovatively uses recombinant technology to produce botulinum toxin,Eliminates the potential safety risks associated with extracting botulinum toxin from Clostridium botulinum, marking a significant technological advancement.。”

According to the terms of the investment agreement, each investorRMB 300 million in totalSubscribing to the additional registered capital of Chongqing Yuyan Pharmaceutical Co., Ltd. for RMB 2.10226 million, corresponding to a total of 8.5714% equity interest after this transaction; among which, Xinkeli Aesthetics contributes RMB 150 million, holding a total of 4.2857% equity interest in Chongqing Yuyan Pharmaceutical Co., Ltd. after this transaction.

According to the terms of the exclusive distribution agreement, Huadong Medicine obtainedChongqing Yuyan Pharmaceutical Co., Ltd.Recombinant Type A Botulinum Toxin Product YY001Exclusive commercial rights in the medical aesthetics indications field in mainland China, Hong Kong, and Macao regionsHuadong Medicine willChongqing Yuyan Pharmaceutical Co., Ltd.Payment of RMB 50 million as the upfront payment, and up to RMB 100 million as the registration milestone payment. Huadong Medicine will be responsible for the commercialization of this product in the medical aesthetics indications within mainland China, Hong Kong, and Macao. Huadong Medicine will also be responsible for YY001 in...Hong Kong Region, AustraliaDoor AreaExclusive clinical development and registration submission in the field of medical aesthetics indications. Yuyan Pharmaceutical will be responsible for the clinical development and registration submission of YY001 in mainland China, as well as the production and supply in global regions. In addition,Huadong Medicine andChongqing Yuyan Pharmaceutical Co., Ltd.Will Fully Leverage Respective Advantages to Collaboratively Develop Long-Lasting Botulinum Toxin Products。Chongqing Yuyan Pharmaceutical Co., Ltd.Huadong Medicine will leverage the advantages of its recombinant protein botulinum toxin technology platform, fully utilizing the resources of its subordinate R&D platforms, clinical research and registration capabilities, as well as its comprehensive strengths in the medical aesthetics field, to carry out technical development, registration applications, and subsequent commercialization work for related products in the field of cooperation.

Chongqing Yuyan Pharmaceutical Co., Ltd.Chairman and Chief Executive OfficerMr. Liu MiaoRepresented, recombinant Type A botulinum toxin YY001 is a new generation, high-quality innovative drug. We are very pleased to have reached a strategic cooperation with Huadong Medicine and Xinkeli Aesthetics. We believe that with Huadong Medicine's experience and capabilities in the research and development, clinical trials, registration, and commercialization of innovative drugs and medical aesthetic products, it will greatly facilitate the process.Chongqing Yuyan Pharmaceutical Co., Ltd.This will lay a solid foundation for the future commercial promotion of YY001. Looking forward to joining hands with Huadong Medicine to deliver a new botulinum toxin product with higher quality and better efficacy.